AMENDMENTS

This listing replaces all prior versions and listings of claims in the application.

1. (Currently amended) A stable liquid medical formulation, which contains a therapeutically effective amount of an antibody in a glutamate buffer ~~and/or a citrate buffer~~ and has a pH between 4.0 and 6.0.

2. (Original) The liquid medical formulation according to claim 1, wherein the concentration of the buffer is between 1 mM and 50 mM.

3. (Currently amended) The liquid medical formulation according to claim 1 ~~or 2~~, which contains an isotonizing agent.

4. (Currently amended) The liquid medical formulation according to ~~any one of claims 1 to~~ claim 3, which contains no salt as an isotonizing agent.

5. (Currently amended) The liquid medical formulation according to claim 3 ~~or 4~~, wherein the isotonizing agent is a polyol.

6. (Original) The liquid medical formulation according to claim 5, wherein the polyol is a sorbitol.

7. (Original) The liquid medical formulation according to any one of claims 3 to 6, wherein the osmotic pressure is between 250 mOsm and 350 mOsm.

8. (Currently amended) The liquid medical formulation according to ~~any one of claims~~ claim 1 ~~to 7~~, which contains a surfactant.

9. (Original) The liquid medical formulation according to claim 8, wherein the surfactant is polysorbate 80.

10. (Original) The liquid medical formulation according to claim 8 or 9, wherein the concentration of the surfactant is between 0.02 mg/mL and 0.10 mg/mL.

11. (Currently amended) The liquid medical formulation according to ~~any one of claims~~ claim 1 ~~to 10~~, wherein the antibody is a human antibody, a humanized antibody, or a chimeric antibody.

12. (Currently amended) The liquid medical formulation according to ~~any one of claims~~ claim 1 ~~to 11~~, wherein the antibody is a monoclonal antibody.

13. (Currently amended) The liquid medical formulation according to ~~any one of claims~~ claim 1 ~~to 12~~, wherein the antibody is IgG.

14. (Original) The liquid medical formulation according to claim 13, wherein the IgG subclass is any one of IgG1, IgG2, or IgG4.

15. (Canceled)

16. (Currently amended) The liquid medical formulation according to ~~any one of claims~~ claim 1 ~~to 15~~, wherein the antibody is an antibody against HLA-DR.

17. (Currently amended) The liquid medical formulation according to ~~any one of claims~~ claim 1 ~~to 15~~, wherein the antibody is an antibody against CD40.

18. (Currently amended) The liquid medical formulation according to ~~any one of claims~~ claim 1 ~~to 17~~, wherein ~~the concentration of~~ the antibody is present in a concentration between approximately 1 and 200 mg/mL.

19. (Original) A stable liquid medical formulation, which contains in a glutamate buffer a therapeutically effective amount of an antibody, a sorbitol as an isotonizing agent, and polysorbate 80 as a surfactant and has a pH between 4.0 and 6.0.

20. (Original) A stable liquid medical formulation, which contains in a glutamate buffer, a therapeutically effective amount of an antibody, a sorbitol as an isotonizing agent, and polysorbate 80 as a surfactant and has a pH between 4.5 and 6.0.

21. (Currently amended) The liquid medical formulation according to any one of claims 1, 19 or [[to]] 20, which contains at least one ~~1 type of~~ stabilizing agent selected from the group consisting of glycine, methionine, cysteine hydrochloride, leucine, lysine hydrochloride, arginine hydrochloride, aspartic acid, ascorbic acid, EDTA, and salts thereof.

22. (Currently amended) A method for producing the liquid medical formulation according to any one of claims 1, 19 or 20 ~~to 21~~, comprising combining a therapeutically effective amount of an antibody with a glutamate buffer and. optionally, an isotonizing agent and a surfactant.

23. (Currently amended) A method for stabilizing an antibody, which comprises combining~~, according to the composition according to any one of claims 1 to 22,~~ a therapeutically effective amount of an antibody, a glutamate buffer ~~and/or a citrate buffer~~, an isotonizing agent, and a surfactant.